Literature DB >> 15633233

Loss of heterozygosity on 10q23.3 and mutation of tumor suppressor gene PTEN in gastric cancer and precancerous lesions.

Yi-Ling Li1, Zhong Tian, Dong-Ying Wu, Bao-Yu Fu, Yan Xin.   

Abstract

AIM: To investigate the loss of heterozygosity (LOH) and mutation of tumor suppressor gene PTEN in gastric cancer and precancerous lesions.
METHODS: Thirty cases of normal gastric mucosa, advanced and early stage gastric cancer, intestinal metaplasia, atrophic gastritis, and atypical hyperplasia were analyzed for PTEN LOH and mutations within the entire coding region of PTEN gene by PCR-SSCP denaturing PAGE gel electrophoresis, and PTEN mutation was detected by PCR-SSCP sequencing followed by silver staining.
RESULTS: LOH rate found in respectively atrophic gastritis was 10% (3/30), intestinal metaplasia 10% (3/30), atypical hyperplasia 13.3% (4/30), early stage gastric cancer 20% (6/30), and advanced stage gastric cancer 33.3% (9/30), None of the precancerous lesions and early stage gastric cancer showed PTEN mutations, but 10% (3/30) of the advanced stage gastric cancers, which were all positive for LOH, showed PTEN mutation.
CONCLUSION: LOH of PTEN gene appears in precancerous lesions, and PTEN mutations are restricted to advanced gastric cancer, LOH and mutation of PTEN gene are closely related to the infiltration and metastasis of gastric cancer.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15633233      PMCID: PMC4205419          DOI: 10.3748/wjg.v11.i2.285

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  31 in total

1.  FcgammaRIIb-mediated negative regulation of BCR signalling is associated with the recruitment of the MAPkinase-phosphatase, Pac-1, and the 3'-inositol phosphatase, PTEN.

Authors:  Kirsty S Brown; Derek Blair; Steven D Reid; Emma K Nicholson; Margaret M Harnett
Journal:  Cell Signal       Date:  2004-01       Impact factor: 4.315

2.  Dual neuroprotective signaling mediated by downregulating two distinct phosphatase activities of PTEN.

Authors:  Ke Ning; Lin Pei; Mingxia Liao; Baosong Liu; Yunzhou Zhang; Wen Jiang; John G Mielke; Lei Li; Yonghong Chen; Youssef H El-Hayek; Michael G Fehlings; Xia Zhang; Fang Liu; James Eubanks; Qi Wan
Journal:  J Neurosci       Date:  2004-04-21       Impact factor: 6.167

3.  Genetic heterogeneity in familial juvenile polyposis.

Authors:  S C Huang; C R Chen; J E Lavine; S F Taylor; R O Newbury; T T Pham; L Ricciardiello; J M Carethers
Journal:  Cancer Res       Date:  2000-12-15       Impact factor: 12.701

4.  PTEN/MMAC1 mutations in endometrial cancers.

Authors:  J I Risinger; A K Hayes; A Berchuck; J C Barrett
Journal:  Cancer Res       Date:  1997-11-01       Impact factor: 12.701

5.  PTEN expression is associated with prognosis for patients with advanced endometrial carcinoma undergoing postoperative chemotherapy.

Authors:  Yasunobu Kanamori; Junzo Kigawa; Hiroaki Itamochi; Habiba Sultana; Mitsuaki Suzuki; Michitaka Ohwada; Toshiharu Kamura; Toru Sugiyama; Yoshihiro Kikuchi; Tsunekazu Kita; Keiichi Fujiwara; Naoki Terakawa
Journal:  Int J Cancer       Date:  2002-08-20       Impact factor: 7.396

6.  PTEN M-CBR3, a versatile and selective regulator of inositol 1,3,4,5,6-pentakisphosphate (Ins(1,3,4,5,6)P5). Evidence for Ins(1,3,4,5,6)P5 as a proliferative signal.

Authors:  Elaine A Orchiston; Deborah Bennett; Nick R Leslie; Rosemary G Clarke; Lucinda Winward; C Peter Downes; Stephen T Safrany
Journal:  J Biol Chem       Date:  2003-10-15       Impact factor: 5.157

7.  Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma.

Authors:  Hensin Tsao; Vikas Goel; Heng Wu; Guang Yang; Frank G Haluska
Journal:  J Invest Dermatol       Date:  2004-02       Impact factor: 8.551

8.  A novel loss-of-function mutation (N48K) in the PTEN gene in a Spanish patient with Cowden disease.

Authors:  Ana Vega; Josema Torres; María Torres; José Cameselle-Teijeiro; Manuel Macia; Angel Carracedo; Rafael Pulido
Journal:  J Invest Dermatol       Date:  2003-12       Impact factor: 8.551

9.  PTEN and TNF-alpha regulation of the intestinal-specific Cdx-2 homeobox gene through a PI3K, PKB/Akt, and NF-kappaB-dependent pathway.

Authors:  Sunghoon Kim; Claire Domon-Dell; Qingding Wang; Dai H Chung; Antonio Di Cristofano; Pier Paolo Pandolfi; Jean-Noel Freund; B Mark Evers
Journal:  Gastroenterology       Date:  2002-10       Impact factor: 22.682

Review 10.  Linking molecular diagnostics to molecular therapeutics: targeting the PI3K pathway in breast cancer.

Authors:  Gordon B Mills; Elise Kohn; Yiling Lu; Astrid Eder; Xianjun Fang; Hongwei Wang; Robert C Bast; Joe Gray; Robert Jaffe; Gabriel Hortobagyi
Journal:  Semin Oncol       Date:  2003-10       Impact factor: 4.929

View more
  16 in total

1.  Airway PI3K pathway activation is an early and reversible event in lung cancer development.

Authors:  Adam M Gustafson; Raffaella Soldi; Christina Anderlind; Mary Beth Scholand; Jun Qian; Xiaohui Zhang; Kendal Cooper; Darren Walker; Annette McWilliams; Gang Liu; Eva Szabo; Jerome Brody; Pierre P Massion; Marc E Lenburg; Stephen Lam; Andrea H Bild; Avrum Spira
Journal:  Sci Transl Med       Date:  2010-04-07       Impact factor: 17.956

Review 2.  Current clinical regulation of PI3K/PTEN/Akt/mTOR signalling in treatment of human cancer.

Authors:  Hui Jun Lim; Philip Crowe; Jia-Lin Yang
Journal:  J Cancer Res Clin Oncol       Date:  2014-08-22       Impact factor: 4.553

Review 3.  Genetic and epigenetic biomarkers in cancer : improving diagnosis, risk assessment, and disease stratification.

Authors:  Mukesh Verma; Daniela Seminara; Fernando J Arena; Christy John; Kumiko Iwamoto; Virginia Hartmuller
Journal:  Mol Diagn Ther       Date:  2006       Impact factor: 4.074

4.  Mechanism of apoptosis involved in gastric mucosal lesions in Tibetans with high-altitude polycythemia.

Authors:  Kang Li; Luobu Gesang; Chaohui He
Journal:  Exp Ther Med       Date:  2017-08-22       Impact factor: 2.447

5.  Allelic loss of 10q23.3, the PTEN gene locus in cervical carcinoma from Northern Indian population.

Authors:  M Moshahid Alam Rizvi; M Shabbir Alam; Syed Jafar Mehdi; Asgar Ali; Swaraj Batra
Journal:  Pathol Oncol Res       Date:  2011-09-08       Impact factor: 3.201

6.  Is NEDD4-1 a negative regulator of phosphatase and tensin homolog in gastric carcinogenesis?

Authors:  Zhen Yang; Xiao-Gang Yuan; Jiang Chen; Nong-Hua Lu
Journal:  World J Gastroenterol       Date:  2012-11-21       Impact factor: 5.742

Review 7.  Recent updates of precision therapy for gastric cancer: Towards optimal tailored management.

Authors:  Moon Kyung Joo; Jong-Jae Park; Hoon Jai Chun
Journal:  World J Gastroenterol       Date:  2016-05-21       Impact factor: 5.742

8.  Unraveling trastuzumab and lapatinib inefficiency in gastric cancer: Future steps (Review).

Authors:  Shouji Shimoyama
Journal:  Mol Clin Oncol       Date:  2013-11-26

9.  Cause and consequences of genetic and epigenetic alterations in human cancer.

Authors:  B Sadikovic; K Al-Romaih; J A Squire; M Zielenska
Journal:  Curr Genomics       Date:  2008-09       Impact factor: 2.236

10.  Molecular heterogeneity in malignant peripheral nerve sheath tumors associated with neurofibromatosis type 1.

Authors:  Laura Thomas; Victor-Felix Mautner; David N Cooper; Meena Upadhyaya
Journal:  Hum Genomics       Date:  2012-09-04       Impact factor: 4.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.